Website
News25/Ratings12
News · 26 weeks44-6%
2025-10-262026-04-19
Mix3590d
- Insider20(57%)
- Other8(23%)
- SEC Filings5(14%)
- Analyst2(6%)
Latest news
25 items- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- INSIDERSEC Form 4 filed by Lu Peng4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 4 filed by Modig Berndt4 - Pharvaris N.V. (0001830487) (Issuer)
- PREvidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 ConferenceZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release (IR) capsule(s) in combination with deucrictibant extended-release (XR) tablet at the Consortium of Independent Immunology Clinics (CIIC) Spring 2026 Conference, which took place from April 17-19, 2026, in Arlington, TX. "Evaluating Safety Margin
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- INSIDERSEC Form 4 filed by Nijdam Anna4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 4 filed by Modig Berndt4 - Pharvaris N.V. (0001830487) (Issuer)
- ANALYSTWolfe Research initiated coverage on Pharvaris N.V. with a new price targetWolfe Research initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $42.00
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- INSIDERSEC Form 4 filed by Nijdam Anna4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 4 filed by Nijdam Anna4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Abele Stefan Andreas3/A - Pharvaris N.V. (0001830487) (Issuer)
- SECSEC Form 20-F filed by Pharvaris N.V.20-F - Pharvaris N.V. (0001830487) (Filer)
- SECSEC Form 6-K filed by Pharvaris N.V.6-K - Pharvaris N.V. (0001830487) (Filer)
- PRPharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateEnrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksCash and cash equivalents of €292 million as of December 31, 2025 ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradyk
- PREvidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet HaematologyResults from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that two articles have been published back-to-back in the same issue of The Lancet Haematology. The articles detail data from the two randomized Phase 2 studies, CHAPTER-1 a
- INSIDERSEC Form 3 filed by new insider Glassman Robert3 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bjork Elisabeth3 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lu Peng3 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nijdam Anna3 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 3 filed by new insider Deschoolmeester Annick3 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 3 filed by new insider Monges Viviane3 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 3 filed by new insider Modig Berndt3 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 3 filed by new insider Meeker David P3 - Pharvaris N.V. (0001830487) (Issuer)